TriOptima, the award-winning provider of post-trade risk management and OTC derivatives infrastructure services, has announced this week several organizational changes.PARA_BREAK_SENTINEL_9f8e7d6c

TriOptima, the award-winning provider of post-trade risk management and OTC derivatives infrastructure services, has announced this week several organizational changes. Mireille Dyrberg becomes Head of Business Strategy, a newly created role, with former TriOptima Asia Pacific CEO, Peter Weibel, taking the reins as CEO for EMEA. In his place, Director of TriOptima Japan, Yutaka Imanishi, becomes Asia Pacific CEO and will also assume full responsibility for TriOptima Japan. The reshuffle comes as TriOptima seeks to react and meet the challenges of the evolving marketplace. TriOptima CEO, Brian Meese (pictured), said that Imanishi had developed and managed client relationships in the firm’s Singapore office before moving to Tokyo to extend their presence in Japan, adding: “He has contributed significantly to our success in Asia, especially with Japanese financial institutions.”

Hedge fund managers use OTC derivatives, often in the form of options and swaps, to help generate alpha. Given the opaque nature of these complex instruments, effective risk management is critical. TriReduce is a portfolio compression service for OTC derivatives dealers on the sell side, whilst TriResolve is a network community service used by buy-side firms as well as global dealers. It provides counterparty exposure management services including portfolio reconciliation and margin call management to help buy-side managers actively manage risk. TriResolve currently handles 6.6million non-cleared OTC derivative trades globally. The firm has offices in New York, London, Stockholm, Singapore and Tokyo.